Evaluating a decision support tool for patients with blood cancers
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
This study tests a new tool called PRIME to see if it helps older adults with blood cancers make treatment choices that better match their personal preferences compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Trial ID | NCT06296368 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the effectiveness of a novel decision support tool called PRIME, which combines values-elicitation with tailored feedback for patients and healthcare providers. The goal is to improve the alignment of treatment decisions with patient preferences in adults diagnosed with hematologic malignancies. By focusing on older adults, the study addresses the challenges of personalizing treatment in a population that often experiences high treatment-related morbidity. The study will compare the outcomes of patients using the PRIME tool against those receiving usual care to determine its impact on patient-reported values-concordance.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 60 and older who are new patients at hematologic malignancies or bone marrow transplant clinics.
Not a fit: Patients with dementia or psychiatric conditions that impair their ability to provide informed consent or participate in the intervention may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could enhance patient satisfaction and improve the quality of care by aligning treatment decisions more closely with patient preferences.
How similar studies have performed: Other studies have shown success with similar decision support tools in improving patient-centered care, indicating a promising approach in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. Written or verbal informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information. 2. Subjects are willing and able to comply with study procedures based on the judgment of the investigator. 3. Age ≥ 60 years at the time of consent. 4. New patient to either the hematologic malignancies clinic or the bone marrow transplant/cellular therapy clinic. Exclusion Criteria All subjects meeting any of the exclusion criteria listed below at baseline will be excluded from study participation: 1\. Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the intervention.
Where this trial is running
Chapel Hill, North Carolina
- Lineberger Comphrehensive Cancer Center at University of North Carolina — Chapel Hill, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Daniel R Richardson, MD, MA, MSc — UNC Lineberger Comprehensive Cancer Center
- Study coordinator: Mireille L Leone
- Email: mireille_leone@med.unc.edu
- Phone: 919-445-0768
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.